Spruce Biosciences Inc reports results for the quarter ended September 30 - Earnings Summary

• Spruce Biosciences Inc SPRB.OQ reported a quarterly adjusted loss of 21 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -30 cents. The mean expectation of seven analysts for the quarter was for a loss of 24 cents per share. Wall Street expected results to range from -29 cents to -19 cents per share.

• Revenue fell 80.4% to $602.00 thousand from a year ago; analysts expected $1.49 million.

• Spruce Biosciences Inc's reported EPS for the quarter was a loss of 21 cents​.

• The company reported a quarterly loss of $8.67 million.

• Spruce Biosciences Inc shares had risen by 12.8% this quarter and lost 81.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 19.3% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "hold"

Wall Street's median 12-month price target for Spruce Biosciences Inc is $2.50

This summary was machine generated from LSEG data November 11 at 03:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)